Toxic Shock Syndrome Skin Lesions
The characteristic skin manifestation of toxic shock syndrome is a diffuse erythroderma (sunburn-like rash) that appears early in the disease course, followed by desquamation (particularly of the palms and soles) 1-2 weeks later during the convalescent phase. 1, 2, 3
Characteristic Skin Findings
Early Phase (Acute Presentation)
- Diffuse erythroderma: A generalized, blanching, macular erythematous rash resembling sunburn that involves the trunk and extremities 1, 3
- Mucosal involvement: Hyperemia of conjunctivae, oropharynx, and vaginal mucosa 2
- Purpuric lesions: In severe cases, purpuric rashes on the nose and distal extremities may develop, potentially progressing to skin necrosis 4
- The wound itself may appear deceptively benign despite systemic toxicity 5
Late Phase (Convalescent - Days 10-14)
- Desquamation: Full-thickness peeling of skin, classically affecting palms and soles, confirms the diagnosis retrospectively 3, 6
- This desquamation is pathognomonic and helps differentiate TSS from other causes of septic shock 7
Management Approach
1. Immediate Recognition and Source Control
The wound must be opened, debrided, and any foreign material (tampons, surgical packing, infected devices) removed immediately 5, 8. This is paramount even if the wound appears benign. Early and aggressive source control directly impacts mortality 8.
2. Antimicrobial Therapy
Administer clindamycin plus an antistaphylococcal agent within 1 hour of recognition 8:
- Clindamycin (required): Suppresses toxin production by inhibiting bacterial protein synthesis 5, 8
- Plus one of the following:
- Vancomycin (if MRSA suspected or prevalent in your area) 1
- Nafcillin or oxacillin (for MSSA)
- Cefazolin (alternative for MSSA)
The clindamycin component is non-negotiable as it directly reduces superantigen-mediated toxin production, which β-lactams alone cannot accomplish 5, 8.
3. Supportive Care
- Aggressive fluid resuscitation: Isotonic crystalloids, 20 mL/kg boluses titrated to hemodynamic parameters 8
- Vasopressor support: If fluid-refractory hypotension develops 8
- Monitor for multi-organ dysfunction: Renal failure, hepatic dysfunction, coagulopathy, and ARDS are common 1, 2
4. Adjunctive Therapy
IVIG may be considered in refractory toxic shock syndrome, though evidence remains unclear 8. The 2013 Surviving Sepsis Campaign guidelines suggest this for cases with persistent hypotension despite standard therapy (Grade 2D recommendation) 8.
Critical Pitfalls to Avoid
Missing the diagnosis early: Initial symptoms (fever, vomiting, diarrhea, malaise) are nonspecific and easily mistaken for viral illness or simple wound infection 9, 6. The rash may not be immediately apparent.
Failing to examine for source: Always perform a pelvic examination in menstruating females presenting with unexplained shock 6. Check all surgical wounds, even if they appear normal 5.
Omitting clindamycin: Using β-lactams alone is insufficient because they do not suppress toxin production 5, 8.
Delaying source control: Waiting for culture results or imaging before removing infected material increases mortality 8. Clinical suspicion should drive immediate action.
Relying on diagnostic criteria: The CDC case definition is useful for surveillance but should not delay treatment in clinically suspicious cases 1. Desquamation occurs late and cannot be used for acute diagnosis 3.
Special Considerations
In children, TSS occurs less frequently but with similar presentation. They are more susceptible due to lack of circulating anti-toxin antibodies 8, 7. Streptococcal TSS (following varicella or with NSAID use) has deeper tissue involvement and higher bacteremia rates than staphylococcal TSS 7.
Thrombotic complications: Rare cases demonstrate peripheral skin necrosis related to thromboinflammatory processes, particularly in patients with prothrombotic conditions 4. Consider anticoagulation in these specific scenarios.
The diagnosis is ultimately clinical and requires high suspicion when encountering fever, hypotension, rash, and multi-organ dysfunction in the appropriate context 1, 2. Confirmation via desquamation or rising anti-TSST-1 antibody titers occurs only during convalescence 3.